Beta Drugs H1 FY26: revenue up 13%, EBITDA up 17%
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts more than Nifty Microcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
H1 FY26 consolidated revenue rose 13% to Rs 203.6 crore and EBITDA rose 17% to Rs 47 crore. Margin improved to 23.08% from 22.36%. Profit after tax excluding debenture interest rose 18% to Rs 28.71 crore; reported profit was nearly flat at Rs 23.95 crore. A Rs 4.56 crore preference-share issue item was exceptional. Flood damage caused a two-week plant shutdown. The review found no material misstatement. FY26 revenue target: Rs 420-430 crore.
Likely positive: revenue, EBITDA, adjusted profit and margins rose. Flood recovery and exports may help, though plant disruption remains a risk.